[go: up one dir, main page]

RU2002119416A - Новые модуляторы дофаминовой нейротрансмиссии - Google Patents

Новые модуляторы дофаминовой нейротрансмиссии

Info

Publication number
RU2002119416A
RU2002119416A RU2002119416/04A RU2002119416A RU2002119416A RU 2002119416 A RU2002119416 A RU 2002119416A RU 2002119416/04 A RU2002119416/04 A RU 2002119416/04A RU 2002119416 A RU2002119416 A RU 2002119416A RU 2002119416 A RU2002119416 A RU 2002119416A
Authority
RU
Russia
Prior art keywords
disorders
group
treatment
pharmaceutical composition
diseases
Prior art date
Application number
RU2002119416/04A
Other languages
English (en)
Other versions
RU2265013C2 (ru
Inventor
Клас СОНЕССОН (SE)
Клас СОНЕССОН
Сусанна УОТЕРС (SE)
Сусанна УОТЕРС
Николас УОТЕРС (SE)
Николас УОТЕРС
Йоаким ТЕДРОФФ (SE)
Йоаким ТЕДРОФФ
Бенгт АНДЕРССОН (SE)
Бенгт АНДЕРССОН
Original Assignee
А. Карльссон Рисерч Аб (Se)
А. Карльссон Рисерч Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by А. Карльссон Рисерч Аб (Se), А. Карльссон Рисерч Аб filed Critical А. Карльссон Рисерч Аб (Se)
Publication of RU2002119416A publication Critical patent/RU2002119416A/ru
Application granted granted Critical
Publication of RU2265013C2 publication Critical patent/RU2265013C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)

Claims (27)

1. Соединение 3-замещенного 4-(фенил-N-алкил)пиперазин или 4-(фенил-N-алкил)пиперидин формулы 1
Figure 00000001
где Х выбран из группы, состоящей из N, СН и С, однако, Х может представлять собой только С, если соединение содержит двойную связь на участке, обозначенном пунктирной линией;
R1 выбран из группы, состоящей из OSO2CF3, OSO2СН3, SOR3, SO2R3, COR3, NO2 и CONHR3, где R3 такой, как определено ниже, и когда Х представляет собой СН или С, R1 может также быть выбран из группы, состоящей из CF3, CN, F, Cl, Br и I;
R2 выбран из группы, состоящей из C1-C4 алкилов, аллилов, СН2SCH3, СН2СН2OCH3, СН2СН2СН2F, СН2CF3, 3,3,3-трифторпропила, 4,4,4-трифторбутила и -(CH2)-R4, где R4 такой, как было определено ниже;
R3 выбран из группы, состоящей из C1-С3 алкилов, CF3 и N(R2)2, где R2 такой, как определено выше;
R4 выбран из группы, состоящей из С3-С6 циклоалкилов, 2-тетрагидрофурана и 3-тетрагидрофурана;
или его фармацевтически приемлемая соль.
2. Соединение по п.1, где Х представляет собой СН или С.
3. Соединение по п.1 или 2, где R1 выбран из группы, состоящей из OSO2CF3, OSO2СН3, SO2СН3, SO2CF3, СОСН3, CF3, CN, CON(СН3)2 и SO2N(СН3)2.
4. Соединение по любому из пп.1-3, где Х представляет собой СН.
5. Соединение по любому из пп.1-4, где R1 выбран из группы, состоящей из SO2CF3, SO2СН3, СОСН3, CF3 и CN, и Х представляет собой СН.
6. Соединение по любому из пп.1-5, где R2 выбран из н-пропила и этила.
7. Соединение по любому из пп.1-6, где Х представляет собой СН, R1 представляет собой SO2СН3, и R2 представляет собой н-пропил.
8. Соединение по любому из пп.1-7, где указанное соединение представляет собой 4-(3-метансульфонилфенил)-1-пропилпиперидин.
9. Фармацевтическая композиция, содержащая соединение по любому из пп.1-8.
10. Фармацевтическая композиция по п.9 для лечения расстройств центральной нервной системы.
11. Фармацевтическая композиция по п.10 для лечения расстройств, опосредованных дофамином.
12. Фармацевтическая композиция по любому из пп.9-11 для лечения состояния, выбранного из группы, состоящей из расстройств движения, таких как ятрогенный и неятрогенный паркинсонизм, дискинезии и дистонии, тики, тремор, болезнь Туретта, заикание и расстройства речи.
13. Фармацевтическая композиция по любому из пп.9-11 для лечения состояний, выбранных из группы, состоящей из ятрогенных и неятрогенных психозов и галлюцозов, включая шизофрению и шизофреноподобные заболевания.
14. Фармацевтическая композиция по любому из пп.9-11 для лечения состояний, выбранных из группы, состоящей из расстройств настроения и тревожных состояний, включая маниакально-депрессивные заболевания, депрессии и обсессивно-компульсивное заболевание.
15. Фармацевтическая композиция по любому из пп.9-11 для лечения состояний, выбранных из группы, состоящей из расстройств нейроразвития и возрастных заболеваний, включая расстройства, связанные с дефицитом внимания, аутизм, брадикинезию, брадифрению, когнитивную дисфункцию.
16. Фармацевтическая композиция по любому из пп.9-11 для лечения состояний, выбранных из группы, состоящей из расстройств сна, расстройств половой функции, расстройств питания, ожирения и головных болей и других болей.
17. Фармацевтическая композиция по любому из пп.9-11 для улучшения моторной функции, когнитивных функций и родственных эмоциональных расстройств при нейродегенеративных расстройствах и расстройствах развития, а также после повреждения мозга, вызванного травматическим, токсическим, воспалительным, инфекционным, неопластическим, сосудистым, гипоксическим или метаболическим причинами при состояниях, выбранных из группы, состоящей из шизофрении и шизофреноподобных заболеваний.
18. Фармацевтическая композиция по любому из пп.9-11 для лечения расстройств, вызванных веществами.
19. Способ лечения расстройства центральной нервной системы у больного, где указанному больному вводится фармацевтически активное количество соединения по любому из пп.1-8.
20. Способ по п.19, предназначенный для лечения расстройств, опосредованных дофамином.
21. Способ по п.19 или 20, предназначенный для лечения состояний, выбранных из группы, состоящей из расстройств движения, таких как ятрогенный и неятрогенный паркинсонизм, дискинезии и дистонии, тики, тремор, болезнь Туретта, заикание и другие расстройства речи.
22. Способ по п.19 или 20, предназначенный для лечения состояний, выбранных из группы, состоящей из ятрогенных и неятрогенных психозов и галлюцозов, включая шизофрению и шизофреноподобные заболевания.
23. Способ по п.19 или 20, предназначенный для лечения состояний, выбранных из группы, состоящей из расстройств настроения и тревожных состояний, включая маниакально-депрессивные заболевания, депрессии и обсессивно-компульсивные болезни.
24. Способ по п.19 или 20, предназначенный для лечения состояний, выбранных из группы, состоящей из расстройств нейроразвития и возрастных заболеваний, включая расстройства, связанные с дефицитом внимания, аутизм, брадикинезию, брадифрению, когнитивную дисфункцию.
25. Способ по п.19 или 20, предназначенный для лечения состояний, выбранных из группы, состоящей из расстройств сна, расстройств половой функции, расстройств питания, ожирения и головных болей и других болей.
26. Способ по п.19 или 20, предназначенный для улучшения моторных функций, когнитивных функций и родственных эмоциональных расстройств при нейродегенеративных расстройствах и расстройствах развития, а также после повреждения мозга, вызванного травматическим, токсическим, воспалительным, инфекционным, неопластическим, сосудистым, гипоксическим или метаболическим причинами при состояниях, выбранных из группы, состоящей из шизофрении и шизофреноподобных заболеваний.
27. Способ по п.19 или 20, предназначенный для лечения расстройств, вызванных веществами.
RU2002119416/04A 1999-12-22 2000-12-22 3-замещенные 4-(фенил-n-алкил)-пиперидины, фармацевтическая композиция на их основе и способы лечения RU2265013C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904724-3 1999-12-22
SE9904724A SE9904724D0 (sv) 1999-12-22 1999-12-22 New modulators of dopamine neurotransmission I

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2005117612/04A Division RU2386623C2 (ru) 1999-12-22 2000-12-22 Новые модуляторы дофаминовой нейротрансмиссии

Publications (2)

Publication Number Publication Date
RU2002119416A true RU2002119416A (ru) 2004-01-10
RU2265013C2 RU2265013C2 (ru) 2005-11-27

Family

ID=20418253

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002119416/04A RU2265013C2 (ru) 1999-12-22 2000-12-22 3-замещенные 4-(фенил-n-алкил)-пиперидины, фармацевтическая композиция на их основе и способы лечения
RU2005117612/04A RU2386623C2 (ru) 1999-12-22 2000-12-22 Новые модуляторы дофаминовой нейротрансмиссии

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2005117612/04A RU2386623C2 (ru) 1999-12-22 2000-12-22 Новые модуляторы дофаминовой нейротрансмиссии

Country Status (30)

Country Link
US (3) US6903120B2 (ru)
EP (3) EP1240142B1 (ru)
JP (3) JP4975928B2 (ru)
KR (2) KR100690133B1 (ru)
CN (2) CN100345833C (ru)
AT (3) ATE491697T1 (ru)
AU (2) AU778422B2 (ru)
BG (2) BG110211A (ru)
BR (1) BR0016611B1 (ru)
CA (1) CA2394602C (ru)
CZ (1) CZ303302B6 (ru)
DE (3) DE60023345T2 (ru)
DK (1) DK1240142T3 (ru)
EE (2) EE200900004A (ru)
ES (2) ES2208461T3 (ru)
HK (2) HK1054229B (ru)
HR (2) HRP20020540B1 (ru)
HU (1) HU229605B1 (ru)
IL (3) IL150351A0 (ru)
MX (1) MXPA02006320A (ru)
NO (2) NO323436B1 (ru)
NZ (2) NZ519595A (ru)
PL (1) PL205093B1 (ru)
RU (2) RU2265013C2 (ru)
SE (1) SE9904724D0 (ru)
SI (1) SI1240142T1 (ru)
SK (1) SK287367B6 (ru)
UA (1) UA73338C2 (ru)
WO (2) WO2001046144A1 (ru)
ZA (1) ZA200204812B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
PE20020690A1 (es) * 2000-11-03 2002-08-23 Upjohn Co Metodo y tratamiento y prevencion de los dolores de cabeza de migranas
EP1575916B1 (en) * 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
NZ552411A (en) 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
US20080176856A1 (en) * 2004-06-18 2008-07-24 Dan Peters Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
KR101319235B1 (ko) * 2004-10-13 2013-10-16 아이백스 인터내셔널 게엠베하 4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
AU2005293755A1 (en) * 2004-10-13 2006-04-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
ATE435216T1 (de) * 2005-02-10 2009-07-15 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission
DE602007013012D1 (de) * 2006-03-10 2011-04-21 Univ New York State Res Found Homotropane mit zns-aktivität
EA015690B1 (ru) * 2006-10-27 2011-10-31 Янссен Фармацевтика, Н.В. Способы лечения расстройств, выражающихся в разрушительном поведении
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
BRPI0810161A2 (pt) * 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
MX2009012716A (es) 2007-06-05 2009-12-14 Nsab Af Neurosearch Sweden Ab Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.
EP2170327B1 (en) * 2007-06-18 2014-10-22 A.Carlsson Research AB Use of dopamine stabilizers
MX2010011498A (es) * 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
BRPI0911772A2 (pt) * 2008-04-29 2017-06-27 Nsab Filial Af Neurosearch Sweden Ab Sverige composto, composição farmacêutica, e, uso do composto.
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
WO2011106039A1 (en) 2010-02-24 2011-09-01 Research Triangle Institute Arylpiperazone opioid receptor antagonists
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2012039660A1 (en) 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
JP6189299B2 (ja) * 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
DK2872145T3 (da) 2012-07-12 2022-06-13 Emalex Biosciences Inc Kondenserede benzazepiner til behandling af tourettes syndrom
US20140088145A1 (en) * 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
DK3057595T3 (da) * 2013-10-18 2020-08-10 Emalex Biosciences Inc Smeltebenzazepiner til behandling af stammen
KR102479759B1 (ko) 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2982898C (en) 2015-05-13 2023-08-29 A. Carlsson Research Ab Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) * 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
AU2017315783C1 (en) 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
AU2017315781B2 (en) * 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
EP3512517B1 (en) 2016-09-15 2025-03-19 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
DK3512506T3 (da) * 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
DK3668509T3 (da) 2017-08-14 2023-02-20 Prilenia Neurotherapeutics Ltd Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
BR112020004045A2 (pt) 2017-08-30 2020-09-01 Prilenia Neurotherapeutics Ltd. formas de dosagem de elevada concentração de pridopidina
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
MX2020002645A (es) 2017-09-08 2021-06-10 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
US20240408038A1 (en) * 2021-09-25 2024-12-12 Alexander Shulgin Research Institute, Inc. Substituted phenylalkylamines
KR20250004058A (ko) * 2022-05-03 2025-01-07 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘을 제조하기 위한 방법 및 중간산물
WO2024172156A1 (ja) * 2023-02-16 2024-08-22 国立大学法人東海国立大学機構 ブラシノステロイド様活性を有する化合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (ru) * 1964-04-14
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
GB1060160A (en) * 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) * 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
GB1560271A (en) * 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2429212A1 (fr) * 1978-06-20 1980-01-18 Synthelabo Derives de phenylpiperazine et leur application en therapeutique
US4267328A (en) * 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
FR2459797A2 (fr) * 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
SE446335B (sv) * 1982-03-30 1986-09-01 Astra Laekemedel Ab Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
AU7162791A (en) * 1989-12-27 1991-07-24 Miroslav Radman Novel system for isolating and producing new genes, gene products and dna sequences
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ATE201669T1 (de) 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
CN1036395C (zh) * 1992-03-19 1997-11-12 约翰韦恩兄弟有限公司 哌嗪衍生物的制备方法
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
CA2288172A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham P.L.C. A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
ES2257864T3 (es) * 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
CA2373921A1 (en) 1999-06-22 2000-12-28 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
WO2002005819A1 (en) 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
ES2246390T3 (es) 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
NZ552411A (en) * 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission

Also Published As

Publication number Publication date
HK1091482A1 (en) 2007-01-19
HRP20020540A2 (en) 2004-12-31
NO324874B1 (no) 2007-12-27
US6903120B2 (en) 2005-06-07
EP1240142B1 (en) 2005-10-19
EP1428822A3 (en) 2009-07-01
DK1240142T3 (da) 2006-02-06
BG65854B1 (bg) 2010-03-31
IL150351A0 (en) 2002-12-01
EE05135B1 (et) 2009-02-16
HK1054229B (zh) 2006-09-22
SE9904724D0 (sv) 1999-12-22
EE200200344A (et) 2003-06-16
EP1240141B1 (en) 2003-11-19
ES2208461T3 (es) 2004-06-16
KR100690133B1 (ko) 2007-03-12
WO2001046145A1 (en) 2001-06-28
AU2570401A (en) 2001-07-03
EP1428822B1 (en) 2010-12-15
BG106841A (bg) 2003-01-31
ATE491697T1 (de) 2011-01-15
CA2394602A1 (en) 2001-06-28
CA2394602C (en) 2009-03-10
BG110211A (en) 2009-02-27
AU2570501A (en) 2001-07-03
HUP0203872A3 (en) 2005-03-29
KR20060006979A (ko) 2006-01-20
WO2001046144A8 (en) 2001-10-04
NZ531680A (en) 2005-10-28
HU229605B1 (en) 2014-02-28
DE60023345D1 (de) 2006-03-02
US20060135531A1 (en) 2006-06-22
NO20065825L (no) 2001-06-25
MXPA02006320A (es) 2004-05-14
DE60006717T2 (de) 2004-08-12
RU2005117612A (ru) 2006-11-20
NO323436B1 (no) 2007-05-07
BR0016611A (pt) 2002-09-03
ATE307113T1 (de) 2005-11-15
CZ303302B6 (cs) 2012-07-25
EE200900004A (et) 2009-04-15
PL205093B1 (pl) 2010-03-31
CN1420869A (zh) 2003-05-28
WO2001046144A1 (en) 2001-06-28
KR100779288B1 (ko) 2007-11-27
HUP0203872A2 (hu) 2003-03-28
IL186448A0 (en) 2008-01-20
NO20022878D0 (no) 2002-06-17
RU2386623C2 (ru) 2010-04-20
CN100345833C (zh) 2007-10-31
HK1054229A1 (en) 2003-11-21
HRP20050784A2 (en) 2006-02-28
CN1765890A (zh) 2006-05-03
US20030139423A1 (en) 2003-07-24
ATE254601T1 (de) 2003-12-15
DE60023345T2 (de) 2006-05-24
SI1240142T1 (sl) 2006-02-28
NZ519595A (en) 2004-05-28
IL150351A (en) 2008-12-29
CN1255382C (zh) 2006-05-10
KR20020067566A (ko) 2002-08-22
CZ20022070A3 (cs) 2002-10-16
RU2265013C2 (ru) 2005-11-27
JP5542740B2 (ja) 2014-07-09
AU778422B2 (en) 2004-12-02
EP1428822A2 (en) 2004-06-16
JP2003518095A (ja) 2003-06-03
ZA200204812B (en) 2003-10-29
US7417043B2 (en) 2008-08-26
HRP20020540B1 (en) 2007-12-31
SK287367B6 (sk) 2010-08-09
ES2246926T3 (es) 2006-03-01
DE60006717D1 (de) 2003-12-24
JP4975928B2 (ja) 2012-07-11
EP1240142A1 (en) 2002-09-18
US20030109532A1 (en) 2003-06-12
JP2009007358A (ja) 2009-01-15
SK8672002A3 (en) 2003-03-04
UA73338C2 (ru) 2005-07-15
PL362253A1 (en) 2004-10-18
BR0016611B1 (pt) 2012-12-11
DE60045395D1 (de) 2011-01-27
EP1240141A1 (en) 2002-09-18
JP2011236214A (ja) 2011-11-24
NO20022878L (no) 2002-08-21

Similar Documents

Publication Publication Date Title
RU2002119416A (ru) Новые модуляторы дофаминовой нейротрансмиссии
RU2002119417A (ru) Новые модуляторы дофаминовой нейротрансмиссии
RU2008108618A (ru) 3, 5-дизамещенные фенил-пиперидины в качестве модуляторов нейротрансмиссии допамина
RU95104322A (ru) Производные дефинила, способы их получения, фармкомпозиция и способ лечения
AR047557A1 (es) Compuestos derivados de piridazina y su uso como agentes terapeuticos
RU2009141300A (ru) N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
AU2003205753B2 (en) Piperdine derivatives
KR950007853A (ko) 종양 치료 방법
RU2012138456A (ru) СОЕДИНЕНИЯ 8-МЕТИЛ-1-ФЕНИЛИМИДАЗО[1,5-a]ПИРАЗИНА
RU2005104435A (ru) Производные 1-гетероциклилалкил-3-сульфонилазаиндола или - азаиндазола в качестве лигандов 5-гидрокситриптамина-6
DE69432638D1 (de) Anwendung von HGF zur Herstellung eines Medikaments gegen Zentralnervensystemstörungen
HUP0101281A2 (hu) Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
RU94043806A (ru) Производные оксазолидин-2-он
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
RU2010141964A (ru) Модуляторы дофаминовой нейротрансмиссии
ATE428711T1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
RU2008110945A (ru) N-оксиды как пролекарства производных пиперазина и пиперидина
RU2006105782A (ru) Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6
RU2008148941A (ru) 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции
RU94046220A (ru) N/гетеро/-арил-n/гетеро/-тетралин-алкилпиперазин, обладающий серотонинергической, допаминергической и адренергической активностью, способ их получения, терапевтическая композиция, применение
ATE402707T1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
CA2450274A1 (en) Benzoxazepine derivatives and their use as ampa receptor stimulators
JP2011518859A5 (ru)

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
HK4A Changes in a published invention
PC41 Official registration of the transfer of exclusive right

Effective date: 20130805

PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181223